Which “small caps” do you like and why?

Looking to add exposure to some of the smaller Canadian (and possibly U.S.) players in the sector, holding for the long haul.

Still conducting DD, but ECB and OGI have piqued my interest thus far. ECB's focus on organic growth and management's proven track record in Pharma are appealing to me.

As far as US firms, I recently added ZYNE as a bit of a YOLO play; they present a compelling case for their products (don't they all?), have patent protection for the next 10+ years, which of course only matters if they work, and have enough cash to stay afloat through 2019. Eagerly awaiting phase II results for ZYN002 (CBD gel) which are due this summer.

Submitted July 12, 2017 at 07:36PM by FamousWalrus
via http://ift.tt/2tOEuD1


Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s